Exchange: NASDAQ·Updated 07:30 PM EST
ACIU logo

ACIU AC Immune SA

$2.09
$0.04
(1.88%)
Today
Closed $2.09
$0.00
(0.00%)
After Hours
Reported EarningsNov 4
Mkt Cap$216.78M
Vol99,324.00

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.
46

Neutral Sentiment

How do you feel about ACIU?

Rayvio_News_Filter
$ACIU 🏥 AC Immune SA reported positive Part 1 week-100 results from its Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease. Timely market event
2
AIIAAIIA_88
$ACIU Holding for Parkinson’s and Alzheimer’s breakthrough. 5-10 years horizon with 10000% potential. JMO
2

Advertisement|Remove ads.